Toxicity and adverse effects of everolimus in the treatment of advanced nonsmall cell lung cancer pretreated with chemotherapy‑Chinese experiences.
Loading...
Date
2015-11
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
BACKGROUND: There is not more treatment selection for advanced nonsmall‑cell lung cancer (NSCLC) patients who had disease progression after
two previous treatments. Everolimus is an oral inhibitor of the mammalian target of rapamycin pathway, which is aberrantly activated in NSCLC.
PATIENTS AND METHODS: Stage IV NSCLC patients, with one or multiple prior chemotherapy regimens, received everolimus 5–10 mg/day with
or without chemotherapy until progression or unacceptable toxicity. The primary objective were toxicity of everolimus and overall disease control
rate (DCR). RESULTS: 22 patients were enrolled. Common ≥grade3 events were stomatitis, dyspnea, vomiting, thrombocytopenia. Overall
disease control rate was 54.5% among 22 patients, 1 had a partial response, and 11 had disease stabilization. Common ≥Grade 3 events were
stomatitis, dyspnea, vomiting, and thrombocytopenia. CONCLUSION: Everolimus was well tolerated, showing the modest clinical activity in heavily
pretreated advanced NSCLC.
Description
Keywords
Everolimus, NSCLC, treatment, toxicity
Citation
Ju Y, Hu Y, Sun S, Wang J, Jiao S. Toxicity and adverse effects of everolimus in the treatment of advanced nonsmall cell lung cancer pretreated with chemotherapy‑Chinese experiences. Indian Journal of Cancer. 2015 Nov; 52(5)Suppl_1: s32-s36.